Faculty/Authors Melissa P. Upton, MDDepartment of Pathology, University of Washington, Seattle CME/CMLE Credit: 1.0 Estimated Completion Time: 1 hour Format: Online Educational Activity and Post-Test Physician Competencies: Patient care, Practice-based learning, System-based practice Eligibility for CME/CMLE credit: Max three attempts. You will have a maximum of three attempts to meet the following criteria:
Default Credit Type: None (You must meet the eligibility requirements in order to obtain CME or SAMs CME credit.) Accreditation Statement: The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). Credit Designation Statement: The American Society for Clinical Pathology (ASCP) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions
To claim CME/CMLE credit for the exercise, do the following:
Faculty DisclosuresThe Journal CME editor and faculty have no relevant financial relationships with commercial interests to disclose.
Technical Considerations
Release Date: 4/25/2025 Review Date:Expiration Date: 4/25/2028
List the molecular markers that are most useful in the work-up of primary and metastatic prostatic adenocarcinoma.
Outline a strategy for selecting or guiding the most appropriate specimen choice(s) for molecular biomarker testing in patients with prostatic adenocarcinoma.
Discuss the potential role of testing for mutations in mismatch repair genes (MMR) and in the homologous recombination repair (HRR) pathway-related genes in patients with prostatic adenocarcinoma.